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Abstract 
Zinc is an important co-factor for metabolism relevant to neurotransmitters, fatty acids, prostaglandins, and 
melatonin, and indirectly affects dopamine metabolism, believed intimately involved in 
attention-deficit/hyperactivity disorder (ADHD). To explore the relationship of zinc nutrition to essential 
fatty acid supplement and stimulant effects in treatment of ADHD, we re-analyzed data from an 18-subject 
double-blind, placebo-controlled crossover treatment comparison of d-amphetamine and Efamol (evening 
primrose oil, rich in gamma-linolenic acid). Subjects were categorized as zinc-adequate (n = 5), borderline 
zinc (n = 5), and zinc-deficient (n = 8) by hair, red cell, and urine zinc levels; for each category, 
placebo-active difference means were calculated on teachers' ratings. Placebo-controlled d-amphetamine 
response appeared linear with zinc nutrition, but the relationship of Efamol response to zinc appeared 
U-shaped; Efamol benefit was evident only with borderline zinc. Placebo-controlled effect size (Cohen's d) 
for both treatments ranged up to 1.5 for borderline zinc and dropped to 0.3-0.7 with mild zinc deficiency. If 
upheld by prospective research, this post-hoc exploration suggests that zinc nutrition may be important for 
treatment of ADHD even by pharmacotherapy, and if Efamol benefits ADHD, it likely does so by improving 
or compensating for borderline zinc nutrition. 
Introduction 
Zinc is necessary for 100 different metalloenzymes and metal-enzyme complexes (Toren 
et al. 1996), many of them in the central nervous system. It contributes to structure and function of 
brain (Black 1998). Among other things, zinc is necessary for conversion of dietary pyridoxine 
(vitamin B6) to its active form, pyridoxal phosphate. Vitamin B6 is necessary in this form for the 
conversion of tryptophan to serotonin. Importantly, zinc is also necessary for production and 
modulation of melatonin, which helps regulate dopamine function (Sandyk 1990; Chen et al. 
1999), widely believed to be a key factor in attention- deficit/hyperactivity disorder (ADHD) and 
its treatment. In fact, Sandyk (1990) hypothesized that parasympathomimetic stimulants, at least 
d-amphetamine, work in ADHD partly via effects on melatonin. 
Both animal data (e.g., Halas and Sandstead 1975; Sandstead et al. 1977; Golub et al. 1996) 
and human findings suggest involvement of zinc deficiency in hyperactivity. Studying moderately 
zinc-deprived monkeys, Golub et al. (1996) reported attentional impairment at levels that did not 
cause growth retardation. They concluded that activity and attention can be affected during early 
stages of zinc deprivation before growth retardation. Human zinc deficiency syndrome includes 
concentration impairment and jitters (Aggett and Harries 1979), and zinc deficiency can delay 
cognitive development (Black 1998). In ADHD, zinc has been reported significantly (p < 0.001) 
deficient compared to controls, with effect size (E.S., Cohen's d) up to 2.4 (Bekaroglu et al. 1996; 
Kozielec et al. 1998; Toren et al. 1996). Starobrat-Hermelin (1998) found a high rate of 
magnesium, zinc, iron, copper, and calcium deficiencies in 116 children with ADHD on the basis 
of serum, red cell, and hair analyses. Hair zinc was lower in ADHD with comorbid 
oppositional-defiant or conduct disorder than in ADHD alone or with anxiety. Bekaroglu et al. 
(1996) concluded that "zinc deficiency may play a role in aetiopathogenesis of ADHD." 
Zinc is also involved in essential fatty acid (EFA) metabolism in several ways (Fogerty et 
al. 1985; Bekaroglu et al. 1996; Poling et al. 1996; Prows and Schroeder 1997). It is a co-enzyme 
for delta-6-desat-urase (e.g., Bettger et al. 1979; Huang et al. 1982; Eder and Kirchgessner, 1996) 
and modulates cyclooxy-genase activity (Sakuma et al. 1996). The latter enzyme is necessary for 
production of cell-regulating prostaglandins and thromboxanes from EFA precursors. In turn, zinc 
absorption from the gut is facilitated by prostaglandins of the 2 series (Song and Adham 1980). 
EFAs and their metabolites are also involved in dopamine and norepinephrine metabolism (Di 
Marzo and Piomelli 1992; Gross et al. 1997; Molderings et al. 1992; Gomez-Nino et al. 1992; 
Sherbourne et al. 1992; Racke et al. 1992; Negishi and Ito 1992) and vice versa (Alanko et al. 
1992; Nadasy et al. 1992; Weidenfeld 1992). Zinc may exert a protective effect against the 
oxidative risk of high n-3 fatty acid intake (Villet et al. 1997). Bekaroglu et al. (1996) reported a 
significant correlation between serum zinc and serum free fatty acid levels in 48 children with 
ADHD, who had significantly lower free fatty acids and zinc than 45 healthy volunteer children 
(E.S. > 1.6; p < 0.001). 
Thus, it is reasonable to suspect a synergism of zinc and EFAs in facilitating and regulating 
dopamine, norepinephrine, and, possibly, serotonin activity, with implications for stimulant 
treatment of ADHD. Arnold et al. (1990) reported a significant correlation of baseline hair zinc 
with placebo-controlled d-amphetamine response in ADHD, but did not explore relationships with 
fatty acids or use additional tissue measures of zinc. This report explores further the relationship of 
zinc nutrition, essential fatty acid effects, and stimulant effects in treatment of ADHD, utilizing 
three measures of zinc nutritional status. The only hypothesis in this exploratory study is a general 
one, that there will be some kind of interaction. 
Methods 
We re-analyzed an available data set from a previously reported double-blind, 
placebo-controlled completely counterbalanced crossover comparison of d-amphetamine and 
Efamol (evening primrose oil, rich in gamma-linolenic acid) as treatment for ADHD (Arnold et al. 
1989). The three treatment conditions were a month long each. The subjects, 6-12-year-old boys, 
had zinc assays on red cells, urine, and hair by standard procedures in a university reference lab. 
The daily dose of d-amphetamine was a timed-release span-sule of either 10 or 15 mg, chosen 
according to the child's size to provide 0.35-0.7 mg/kg body weight. The Efamol dose was 4 
capsules twice a day, supplying 320 mg gamma-linolenic acid (18:3n-6) per day. Conners 39-item 
Teacher Rating Scale and the seven-item Davids Hyperkinetic Rating Scale were collected from 
teachers at the end of each of the three conditions (Conners 1969; Davids 1971). 
A pediatrician (S.P.) not familiar with the subjects or the data but experienced in 
interpreting trace mineral status blindly classified the 18 subjects as having adequate zinc nutrition 
(n = 5), borderline zinc nutrition (n = 5), or frank (though mild) zinc deficiency (n = 8), based on 
clinical scrutiny of red cell, hair, and urine zinc levels without seeing the subjects. No single tissue 
test is definitive for zinc nutrition, and the tissue of interest (CNS) was not accessible for assay. 
Therefore, S.P. based the classification on all three 
  D-amphetamine-placeo difference scores  
 Adequate zinc  Borderline Zinc deficient 
Behavioral measure (n = 5)  (n = 5) (n = 8) 
Conners Teacher Sum 23.60 ± 22.68  20.00 ± 13.60 15.13 ± 28.76 
(39 items)     
Hyperactivity factor 13.20 ± 12.32  13.80 ± 9.01 10.63 ± 15.87 
Hyperactivity index 10.40 ± 8.32  7.80 ± 5.22 6.38 ±11.64 
Davids Hyperkinetic Scale 4.00 ± 3.81  3.60 ± 3.51 1.63 ± 5.88 
(sum of first 6 items     
by teacher)     
aPlacebo scores minus d-amphetamine scores: means ± SD. Higher difference score is better response. The 
zinc deficiency (third column) is mild, picked up only by hair, red cell, and urine assays. 
Table 1. Teacher-Rated Response to Dextroamphetamine by Zinc-Nutrition Categoriesa 
available assays, using a dynamic model of zinc balance as the net of intake/stores and excretion, 
with possible variations from tissue to tissue. In this model, high urine or hair zinc could be a result 
of either high intake or excess wasting of the normal intake, and normal red cell zinc is only 
suggestive of normal neuronal zinc because zinc level can vary from one tissue to another. The 
three tissue levels were clinically integrated thusly: If all three were high or all three normal, zinc 
nutrition was classified adequate. If all three were low, it was classified deficient. In the cases with 
"splits," hair level was first examined as the best measure of long-term zinc availability to the 
CNS: if it was definitely low, the classification was zinc deficiency; if hair zinc was high or within 
normal variability, the other tissue levels were consulted. With normal hair zinc, high or normal 
red cell zinc yielded a classification of adequate, and low red cell level yielded a classification of 
borderline. If hair zinc was high, normal red cell and urine levels or high red cell level with normal 
urine level yielded a classification of adequate, while normal red cell level with high or low urine 
level or low red cell level with normal urine level yielded a classification of borderline. 
Mean placebo-Efamol and mean placebo-d-amphetamine differences from the completely 
counterbalanced crossover trial were then calculated for each of these three blind zinc-nutrition 
groupings on Conners teacher ratings (total, hyperactivity factor, and hyperactivity index) and 
Davids Hyperkinetic Scale teacher ratings (Tables 1 and 2). Statistical comparison tests were not 
done because of the small group sizes in this heuristic exploration; rather, effect size implications 
for possible future studies are emphasized. 
  Efamol-placeo difference scores  
 Adequate zinc Borderline Zinc deficient 
Behavioral measure (n = 5) (n = 5) (n = 8) 
Conners Teacher Sum -0.80 ± 13.41 18.60 ± 11.93 6.25 ± 19.41 
(39 items)    
Hyperactivity factor -0.80 ± 3.42 12.00 ± 9.27 4.25 ± 8.83 
Hyperactivity index 0.20 ± 2.59 6.80 ± 4.87 2.38 ± 5.93 
Davids Hyperkinetic Scale 0.00 ± 1.22 3.60 ± 2.79 0.63 ±2.13 
(sum of first 6 items    
by teacher)    
aPlacebo scores minus Efamol scores: means ± SD. Higher difference score is better response. The zinc 
deficiency (third column) is mild, picked up only by hair, red cell, and urine assays. 
Table 2. Teacher-Rated Response to Gamma-Linolenic Acid (Efamol) by Zinc-Nutrition Categoriesa 
Results 
Descriptive statistics (mean ± SD) for placebo-corrected behavioral effects of 
d-amphetamine for each zinc nutritional classification are shown in Table 1, and similarly for 
placebo-corrected effects of Efamol in Table 2. For visual comparison, the Conners teacher 
hyperactivity index means are graphed in Figure 1 for both the d-amphetamine-placebo and 
Efamol-placebo differences. 
Inspection of the tables and figure suggests that d-amphetamine effect is associated 
linearly or perhaps asymptotically with level of zinc nutrition, while Efamol effect seems more 
quadratic (inverted U-shaped curve). Efamol had no effect in the five subjects with adequate 
baseline zinc nutrition, was practically as effective as d-amphetamine in the five subjects with 
borderline zinc nutrition, and faded in effect in the eight subjects with mild zinc deficiency. 
The potential clinical significance is revealed by comparison of effect sizes (Cohen's d, 
mean difference divided by SD). An effect size of 0.3 is considered small, 0.5 moderate, and 1.0 
large. For comparison, the pooled mean placebo-stimulant difference in most controlled studies 
has an effect size of about 0.9-1.2. In this analysis, the placebo-controlled effect size of 
d-amphetamine is well over 1.0 on all measures in the presence of adequate or even borderline zinc 
nutrition but only 0.3-0.6 (depending on the measure) in the presence of mild zinc deficiency. The 
placebo-controlled effect size of Efamol is nil in the presence of adequate zinc nutrition, but 
exceeds 1.3 on most measures in the presence of borderline zinc deficiency. In fact, both Efamol 
and d-amphetamine show placebo-controlled effect sizes up to 1.5 (1.2-1.6 for Efamol, 1.0-1.5 for 
d-amphetamine) with borderline zinc nutrition, dropping to <0.7 with mild zinc deficiency. This 
suggests a moderator effect size of about 0.7-0.8 for zinc deficiency compared to borderline zinc 
status. 
Discussion 
If upheld by further study, these data suggest the following: (1) zinc nutrition may be 
important for treatment of ADHD even by pharmacotherapy, and (2) if Efamol benefits children 
with ADHD, it likely does 
 
Fig. 1. Mean difference scores (±SE) between placebo and the two active treatments (d-amphetamine, 
Efamol) on teacher Conners hyperactivity index, by zinc-nutrition category determined from hair, red cell, 
and urine zinc assays. Placebo-controlled amphetamine benefit appears linear with zinc nutrition. Efamol 
benefit appears quadratic, highest with borderline zinc. 
so by improving or compensating for borderline zinc nutrition; if zinc nutrition is frankly deficient 
(even mild deficiency), Efamol cannot make up for it. It is important to note that the children in 
this study were not clinically diagnosed as zinc-deficient; the deficiency was picked up only by the 
tissue assays. 
It is not clear whether the interaction of d-amphetamine with zinc nutritional status, if 
upheld by further study, would also extend to other stimulants or to antidepressants. It is also not 
clear whether the Zn-moderated effect of Efamol, if upheld by further study, would apply to other 
essential fatty acid preparations, especially those with a heavy emphasis on the n-3 series. If the 
mechanism of any Efamol benefit is by improving absorption of borderline amounts of dietary 
zinc, this may be specific to the n-6 series, especially gamma-linolenic acid, the precursor of 
dihomo-gamma-linolenic acid, which is the precursor of the series 2 prostaglandins most 
implicated in gut absorption of zinc. 
The proportions of this ADHD sample classified as mildly zinc-deficient (44%) and 
borderline in zinc nutrition (28%) deserve some comment. Though apparently high, they are not 
inconsistent with other published reports. As background, Sandstead (1973) found generally 
suboptimal zinc levels in U.S. diets. Bekaroglu et al. (1996) reported mean serum zinc of 60.6 ± 
9.9 mcg/dL in 33 boys and 15 girls with ADHD compared to 105.8 ± 13.2 mcg/dL in healthy 
volunteers (30 boys and 15 girls). Toren et al. (1996) reported significantly lower serum zinc levels 
and more variance in 39 boys and four girls age 6-16 years with ADHD than in a control group of 
28 age-matched healthy controls; 35% of subjects with ADHD fell outside the normal control 
range of 8.3-19.2 mcmol/L, most of these (30%) being lower. Rates based on a single tissue assay 
might be considered a lower-bound estimate of deficiency prevalence; additional tissues, as used 
in the study reported here, might discover more subtle deficiency and borderline states. 
It is interesting to note that, though multiple studies in animals and humans support an 
association of zinc nutritional state with behavior relevant to ADHD, one study that did not was 
from the Dunedin (New Zealand) developmental study cohort, in which McGee et al. (1990) found 
no significant correlation of hair or serum zinc with parent or teacher hyperactivity ratings. (This 
was a general epidemiologic study, not a comparison of diagnosed ADHD to normal controls.) A 
negative trial of Efamol for ADHD was also reported from New Zealand (Aman et al. 1987). As 
with selenium, iodine, and some other trace minerals, zinc intake can vary geographically. The 
amount of zinc in the soil and in the local flora and fauna, as well as endemic dietary habits, can 
influence the amount of zinc ingested. It might be illuminating to compare the New Zealand diet 
and its zinc content to the U.S. diet and zinc content. 
The discussion above is entirely speculative at this point, of course. No definite 
conclusions should be drawn from these preliminary data, which are presented for their heuristic 
value in guiding further, hypothesis-based, prospective research. 
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